HISTORY will be made in English Football League on Saturday (10) when sikh brothers Bhups and Sunny Singh Gill will become the first pair of British South Asians to officiate in the same Championship game.
Their father, Jarnail Singh, was the first turbaned sikh to have been a referee in the English Football League. Both brothers will be part of the officiating team for Saturday's match between Bristol City and Nottingham Forest.
Professional Game Match Officials Limited (PGMOL) - the body responsible for appointing match officials across the EFL - has confirmed Bhups as one of two assistant referees for the Championship match at Ashton Gate, with Sunny named fourth official.
Bhupinder, 36, a PE teacher started refereeing in his mid-teens and is also England's highest-ranked South Asian assistant referee. His brother, Sunny, a year to him is a prison officer at HMP Feltham and started refereeing at the age of 15. He is also the most senior British South Asian referee in the country.
The brothers from Berkshire have officiated in the Championship this season but never in the same game.
Moreover, the rare occasion of both the brothers being part of the same match, has been greeted by the Punjabi community.
Shadow secretary of State for International Development, Preet Kaur Gill, who is also Britain's first Sikh female Member of Parliament, told Sky Sports News: "I think it's (going to be) wonderful to see the two brothers refereeing and the likelihood of them refereeing a Championship game is brilliant."
Former Premier League match official Howard Webb, who refereed the 2010 World Cup final, told Sky Sports News that he is thrilled to see Bhups and Sunny's progress.
"I'm absolutely thrilled to see the progress that Sunny and Bhups have made in the game. I've had my eye on them for quite some time," said Webb.
"I go back with their dad for quite some time, we worked in the Football League together. And Jarnail Singh, in addition to being a really, really good referee, is just a wonderful guy. He was always a pleasure to work with.
"They (Bhups and Sunny) are athletic, they know how to manage people, all these skills that you need to be successful. If you don't have them, you don't survive in the professional game. These guys have done more than survive, they've excelled and I think will continue to do so," he added.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.